コンテンツへスキップ
Merck
  • Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes.

Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes.

American journal of ophthalmology (2014-01-15)
Ajay E Kuriyan, Kathleen D Weiss, Harry W Flynn, William E Smiddy, Audina M Berrocal, Thomas A Albini, Darlene Miller
要旨

To report the clinical settings, antibiotic susceptibilities, and outcomes of endophthalmitis caused by Streptococcus species. Retrospective, observational case series. Single-center study evaluating all patients with culture-positive endophthalmitis caused by Streptococcus species between January 1, 2000, and December 31, 2011. Study criteria were met by 63 patients. The most common clinical settings were bleb associated (n = 17; 27%), after intravitreal injection (n = 16; 25%), and after cataract surgery (n = 13; 21%). The isolates were Streptococcus viridans (n = 47; 71%), Streptococcus pneumoniae (n = 13; 21%), and β-hemolytic Streptococci (n = 5; 8%). Sixty (95%) of 63 isolates were susceptible to vancomycin, 47 (98%) of 48 isolates were susceptible to ceftriaxone (third-generation cephalosporin), and 57 (93%) of 61 isolates were susceptible to levofloxacin (third-generation fluoroquinolone). Between the first and second half of the study, the minimal inhibitory concentration of antibiotics required to inhibit 90% of isolates increased by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the same for vancomycin. Initial treatment was vitreous tap (49; 78%) or pars plana vitrectomy (14; 22%); all received intravitreal antibiotics. Visual acuity outcomes were variable: best-corrected visual acuity was 20/400 or better in 16 (25%) patients and worse than 20/400 in 47 (75%) patients. Evisceration or enucleation was performed in 16 (25%) patients. Streptococcus isolates generally had high susceptibility rates to commonly used antibiotics. Higher antibiotic minimal inhibitory concentrations were required to inhibit 90% of isolates in vitro in the second half of the study period compared with the first half. Despite prompt treatment, most patients had poor outcomes.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
バンコマイシン 塩酸塩 Streptomyces orientalis由来, ≥900 μg per mg (as vancomycin base)
Sigma-Aldrich
バンコマイシン 塩酸塩 Streptomyces orientalis由来, ≥85% (Vancomycin B)
Sigma-Aldrich
アミカシン 水和物, aminoglycoside antibiotic
Sigma-Aldrich
バンコマイシン 塩酸塩 Streptomyces orientalis由来, BioReagent, suitable for plant cell culture
Sigma-Aldrich
アミカシン 二硫酸塩, potency: 674-786 μg per mg (as amikacin base)
USP
Ceftazidime pentahydrate, United States Pharmacopeia (USP) Reference Standard
Millipore
バンコマイシン 塩酸塩, suitable for microbiology
Sigma-Aldrich
バンコマイシン 塩酸塩 Streptomyces orientalis由来, meets USP testing specifications
Ceftazidime, European Pharmacopoeia (EP) Reference Standard
アミカシン 二硫酸塩, European Pharmacopoeia (EP) Reference Standard
Amikacin, European Pharmacopoeia (EP) Reference Standard
システム適合性用アミカシン, European Pharmacopoeia (EP) Reference Standard
Ceftazidime for peak identification, European Pharmacopoeia (EP) Reference Standard